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Condensation: Pregnancy in the setting of COVID-19 disease secondary to SARS-COV-2 33 
infection is associated with higher rates of miscarriage, preterm birth, preeclampsia, cesarean and 34 
perinatal death. There were no reported cases of vertical transmission. 35 
 36 
Short title: Coronavirus infections in pregnancy 37 
 38 
39 
AJOG AT A GLANCE 40 
 41 
A. Why was this study published? 42 
COVID-19 disease secondary to SARS-COV-2 infection is a worldwide pandemic with an 43 
increasing number of confirmed cases everyday. Little s known about the effect of CoV 44 
(coronavirus)-related infections during pregnancy.  45 
B. What are the key findings? 46 
C. Pregnancy in the setting of CoV infection is associated with higher rates of miscarriage, 47 
preterm birth, preeclampsia, cesarean delivery and perinatal death (7-11%). There were no 48 
reported cases of vertical transmission. 49 
D. What does this study add to what is already known? 50 
This is the first systematic review exploring pregnancy and perinatal outcomes of CoV 51 
infections occurring during pregnancy. Although limited, these data can guide and enhance 52 
prenatal counselling of women with COVID-19 infection occurring during pregnancy. 53 
Evidence is accumulating rapidly, so these data may need to be updated soon. 54 
 55 
 56 
  57 
ABSTRACT 58 
Objective: The aim of this systematic review was to report pregnancy and perinatal outcomes of 59 
Coronavirus (CoV) spectrum infections, and particularly COVID-19 disease due to SARS-COV-2 60 
infection during pregnancy. 61 
Data sources: Medline, Embase, Cinahl and Clinicaltrials.gov datab ses were searched 62 
electronically utilizing combinations of word variants for “coronavirus” or “severe acute respiratory 63 
syndrome” or “SARS” or “Middle East respiratory syndrome” or “MERS” or “COVID-19” and 64 
“pregnancy”. The search and selection criteria were r stricted to English language.  65 
Study eligibility criteria: Inclusion criteria were pregnant women with a confirmed Coronavirus 66 
related illness, defined as either SARS, MERS or COVID-19. 67 
Study appraisal and synthesis methods: We used meta-analyses of proportions to combine data 68 
and reported pooled proportions. The pregnancy outcomes observed included miscarriage, preterm 69 
birth, pre-eclampsia, preterm prelabor rupture of membranes, fetal growth restriction, and mode of 70 
delivery. The perinatal outcomes observed were fetal distress, Apgar score < 7 at five minutes, 71 
neonatal asphyxia, admission to neonatal intensive car  unit, perinatal death, and evidence of 72 
vertical transmission.  73 
Results: 19 studies including 79 women were eligible for this systematic review: 41 pregnancies 74 
(51.9%) affected by COVID-19, 12 (15.2%) by MERS, and 26 (32.9%) by SARS. An overt 75 
diagnosis of pneumonia was made in 91.8% and the most common symptoms were fever (82.6%), 76 
cough (57.1%) and dyspnea (27.0%). For all CoV infections, the rate of miscarriage was 39.1% 77 
(95% CI 20.2-59.8); the rate of preterm birth < 37 weeks was 24.3% (95% CI 12.5-38.6); premature 78 
prelabor rupture of membranes occurred in 20.7% (95% CI 9.5-34.9), preeclampsia in 16.2% (95% 79 
CI 4.2-34.1), and fetal growth restriction in 11.7% (95% CI 3.2-24.4); 84% were delivered by 80 
cesarean; the rate of perinatal death was 11.1% (95CI 84.8-19.6) and 57.2% (95% CI 3.6-99.8) of 81 
newborns were admitted to the neonatal intensive car  unit. When focusing on COVID-19, the most 82 
common adverse pregnancy outcome was preterm birth < 37 weeks, occurring in 41.1% (95% CI 83 
25.6-57.6) of cases, while the rate of perinatal deth was 7.0% (95% CI 1.4-16.3). None of the 41 84 
newborns assessed showed clinical signs of vertical transmission. 85 
Conclusion: In mothers infected with coronavirus infections, including COVID-19, >90% of whom 86 
also had pneumonia, PTB is the most common adverse p egnancy outcome. Miscarriage, 87 
preeclampsia, cesarean, and perinatal death (7-11%) were also more common than in the general 88 
population. There have been no published cases of clinical evidence of vertical transmission. 89 
Evidence is accumulating rapidly, so these data mayneed to be updated soon. The findings from 90 
this study can guide and enhance prenatal counseling of women with COVID-19 infection 91 
occurring during pregnancy. 92 
 93 




INTRODUCTION  98 
Coronavirus (CoV) is an enveloped, positive-stranded ribonucleic acid (RNA) virus of the family of 99 
Coronaviridae and belonging to the Nidovirales order,1 generally causing respiratory and 100 
gastrointestinal infections that might range from mild, self-limiting conditions to more serious 101 
disorders, such as viral pneumonia with systemic impairment.2  102 
In the last two decades, CoV has been responsible for two large epidemics: the Severe Acute 103 
Respiratory Syndrome (SARS) that infected 8098 people with a case-fatality rate of about 10.5%,3 104 
and the Middle East Respiratory Syndrome (MERS) with a total of 2519 laboratory-confirmed 105 
cases and a case–fatality rate of 34.4%.4 106 
Towards the end of 2019, a novel mutation of CoV (labe led as SARS-COV-2) was identified as the 107 
cause of a severe respiratory illness – called COVID-19 - that typically presents with fever and 108 
cough.5 Infected people show abnormal findings at diagnostic imaging, suggestive for pneumonia.  109 
After beginning as an epidemic in China, COVID-19 infection has rapidly spread in many other 110 
countries and the number of affected cases continues to increase significantly on a daily basis. The 111 
overall mortality rate ranges from 3% to 4% according to the World Health Organization reports,6 112 
but a higher rate of patients require admission to the intensive care unit (ICU).7 113 
It is well known that physiologic maternal adaptations to pregnancy predispose pregnant women to 114 
a more severe course of pneumonia, with subsequent higher maternal and fetal morbidity and 115 
mortality,1,8 but there is a lack of data in the literature about the effect of CoV infections during 116 
pregnancy, thus limiting both counseling and management of these patients. 117 
Objective 118 
The aim of this systematic review was to report pregnancy and perinatal outcomes of CoV spectrum 119 




Search strategy and selection criteria 124 
This review was performed according to a priori designed protocol recommended for systematic 125 
reviews and meta-analysis.9-11 Medline, Embase, Cinahl and Clinicaltrials.gov datab ses were 126 
searched electronically on 03/13/2020, utilizing combinations of the relevant medical subject 127 
heading (MeSH) terms, key words, and word variants for “coronavirus” or “severe acute respiratory 128 
syndrome” or “SARS” or “Middle East respiratory syndrome” or “MERS” or “COVID-19” and 129 
“pregnancy”. The search and selection criteria were r stricted to English language. Reference lists 130 
of relevant articles and reviews were hand searched for additional reports. PRISMA and MOOSE 131 
guidelines were followed.12-14  132 
Inclusion criteria were pregnant women with a confirmed Coronavirus spectrum illness, defined as 133 
either SARS, MERS or COVID-19 infection. 134 
The pregnancy outcomes observed were: 135 
• Preterm birth (PTB) (either before 37 or 34 weeks of gestation) 136 
• Pre-eclampsia (PE) 137 
• Preterm prelabor rupture of membranes (pPROM) 138 
• Fetal growth restriction (FGR) 139 
• Miscarriage, as defined by authors 140 
• Cesarean mode of delivery 141 
The perinatal outcomes observed were: 142 
• Fetal distress (as defined by original authors) 143 
• Apgar score < 7 at five minutes 144 
• Neonatal asphyxia (as defined by original authors) 145 
• Admission to neonatal intensive care unit (NICU) 146 
• Perinatal death, including both stillbirth and neonatal death 147 
• Evidence of vertical transmission, defined as the presence of clinical signs of mother-to-148 
child transmission in the antenatal or perinatal period 149 
 150 
Furthermore, we aimed to perform a sub-group analysis according to the trimester of pregnancy at 151 
infection and the type of Coronavirus. 152 
Data from studies reporting the incidence of these outcomes in pregnancies with CoV spectrum 153 
infections were considered eligible for analysis. For the purpose of the analysis, we included only 154 
full-text articles with data of pregnant women who already delivered; we excluded data regarding 155 
on-going pregnancies. Furthermore, as these are relatively rare infections occurring during 156 
pregnancy with the majority of data coming from studies with small sample sizes, case reports and 157 
case series were also included in the analysis. Studies reporting cases of infective pneumonia or 158 
other respiratory disorders during pregnancy caused by other viral agents were excluded. We also 159 
excluded studies pediatric series on newborns and chil ren from which maternal and pregnancy 160 
information could not be extrapolated.  161 
Two authors (DDM, GS) reviewed all abstracts independently. Agreement regarding potential 162 
relevance or inconsistencies was reached by consensu  or resolved by discussion with a third 163 
reviewer (FDA). Full text copies of applicable papers were obtained, and the same reviewers 164 
independently extracted relevant data regarding study characteristics and pregnancy outcome. If 165 
more than one study was published on the same cohort with identical endpoints, the report 166 
containing the most comprehensive information on the population was included to avoid 167 
overlapping populations.  168 
 169 
Data analysis 170 
We used meta-analyses of proportions to combine data and reported pooled proportions (PP). 171 
Funnel plots (displaying the outcome rate from individual studies versus their precision (1 per SE)) 172 
were carried out with an exploratory aim. Tests for funnel plot asymmetry were not used when the 173 
total number of publications included for each outcme was <10. In this case, the power of the tests 174 
is too low to distinguish chance from real asymmetry.  175 
Between-study heterogeneity was explored using the I2 statistic, which represents the percentage of 176 
between-study variation that is due to heterogeneity rather than chance. A value of 0% indicates no 177 
observed heterogeneity, whereas I2 values ≥50% indicate a substantial level of heterogeneity. A 178 
random effect model was used to compute the pooled data analyses. All proportion meta-analyses 179 
were carried out by using StatsDirect version 2.7.9 (StatsDirect, Ltd, Altrincham, Cheshire, United 180 
Kingdom). 181 
Quality assessment of the included studies was assessed using the methodological quality and 182 
synthesis of case series and case reports described by Murad et al.15 According to this tool, each 183 
study is judged on four broad perspectives: the selction of the study groups, the ascertainment and 184 
the causality of the outcome observed, and the reporting of the case. A study can be awarded a 185 
maximum of one star for each numbered item within te Selection and Reporting categories, two 186 
stars for Ascertainment and four stars for Comparability. 15 Given emergency-need for this 187 
guidance, PROSPERO registration was not sought. 188 
 189 
RESULTS   190 
Study selection and characteristics  191 
538 articles were identified, 27 were assessed withrespect to their eligibility for inclusion and 19 192 
studies were included in the systematic review (Table 1, Figure 1, Supplementary Table 1). 193 
These 19 studies16-34 included 79 pregnancies affected by CoV infections. The mean maternal age 194 
was 34.6. Out of the 79 pregnancies affected by CoV infections: 41 (51.9%) were affected by 195 
COVID-19, 12 (15.2%) by MERS and 26 (32.9%) by SARS. 196 
Clinical symptoms and laboratory parameters in the ov rall population of pregnant with CoV 197 
infections are reported in Table 2. An overt diagnosis of pneumonia was made in 91.8% (54/57) of 198 
cases (when available, radiological findings suggestiv  for pneumonia are reported in 199 
Supplementary Table 2). The most common symptom was fever that affected 82.6% (64/76) of 200 
women, followed by cough (57.1%, 44/77) and dyspnea (27%, 21/77). Lymphopenia and elevated 201 
liver enzymes were found in 79.8% (40/48) and 36.6% (9/26) of cases, respectively. 34.1% (22/70) 202 
of pregnant women affected by CoV infections were admitted to ICU and 26.3% (16/69) required 203 
mechanical ventilation. Maternal death occurred in 12.3% (9/79) of all reported CoV-related 204 
diseases cases. Of note, the rates of admission to ICU (9.3% vs 44.6% vs 53.3%), need for 205 
mechanical ventilation (5.4% vs 40.9% vs 40%) and maternal death (0% vs 28.6% vs 25.8%) were 206 
significantly lower in pregnancies affected by COVID-19, compared to MERS and SARS 207 
respectively (Supplementary Table 3). 208 
The majority of women affected by CoV infections were usually treated first with broad spectrum 209 
antibiotics in 89.3% of cases (49/52) and then with antiviral therapy and steroids in 67.7% (37/51) 210 
and 29.8% (12/31) of cases (Table 3; Supplementary T ble 4). 211 
The results of the quality assessment of the included studies are presented in Supplementary 212 
Table 5.  213 
 214 
Synthesis of the results 215 
In the overall population of pregnancies infected with CoV, The rate of miscarriage for CoV 216 
infections was 39.1% (8/21 – 95% CI 20.2-59.8). Therat s of PTB < 37 and 34 weeks of gestation 217 
were 24.3% (14/56 – 95% CI 12.5-38.6) and 21.8% (11/56 - 95% CI 12.5-32.9), respectively; 218 
pPROM occurred in 20.7% (6/34 – 95% CI 9.5-34.9), while the rate of pregnancies experiencing 219 
PE and FGR was 16.2% (2/19 – 95% CI 4.2-34.1) and 11.7% (2/29 – 95% CI 3.2-24.4), 220 
respectively. The rate of CD was 83.9% (50/58 – 95% CI 73.8-91.9) (Table 4; Table 5). The rate of 221 
perinatal death was 11.1% (5/60 – 95% CI 84.8-19.6) including three stillbirths and two neonatal 222 
deaths (further details are provided in Supplementary T ble 6). Thirty-four point six percent (15/44 223 
– 95% CI 20.3-49.5) of fetuses suffered from fetal distress and 57.2% (3/12 – 95% CI 3.6-99.8) of 224 
newborns was admitted to NICU. The rate of Apgar score < 7 at five minutes was 6.1% (1/48 – 225 
95% CI 1.3-13.9), but no case of neonatal asphyxia were reported. Finally, none of the newborns 226 
showed signs of vertical transmission during the follow-up period (Table 6; Table 7). 227 
COVID-19 228 
Six studies16-21 reported information on COVID-19 infection during pregnancy. There was no data 229 
on miscarriage for COVID-19 infection occurring during the first trimester. The rates of PTB < 37 230 
and 34 weeks of gestation were 41.1% (14/32 – 95% CI 25.6-57.6) and 15% (4/32 - 95% CI 3.9-231 
31.7), respectively. pPROM occurred in 18.8% (5/31 – 95% CI 0.8-33.5), while the rate of 232 
pregnancies experiencing PE was 13.6% (1/12 – 95% CI 1.2-36.0), with no reported cases of FGR. 233 
The rate of CD was 91% (38/41 – 95% CI 81.0-97.6) (Table 5). The rate of perinatal death was 7% 234 
(2/41 – 95% CI 1.4-16.3) including one stillbirth and one neonatal death; 43% (12/30 – 95% CI 235 
15.3-73.4) of fetuses had fetal distress and 8.7% (1/10 – 95% CI 0.01-31.4) of newborns were 236 
admitted to NICU. The rate of Apgar score < 7 at five minutes was 4.5% (1/41 – 95% CI 0.4-12.6) 237 
and no case of neonatal asphyxia was reported. Finally, one of the newborns showed signs of 238 
vertical transmission during the follow-up period (Table 7). 239 
 240 
MERS 241 
Seven studies22-28 reported information on MERS infection during pregnancy. There was no data on 242 
miscarriage for MERS infection occurring during the first trimester. The rate of PTB was 32.1% 243 
(3/11 - 95% CI 10.0-59.8), all occurring before 34 weeks of gestation. Preeclampsia occurred in 244 
19.1% (1/7 – 95% CI 1.1-51.3) respectively, while no case of pPROM or FGR was reported in these 245 
studies. The rate of CD was 61.8% (5/8 – 95% CI 32.7-86.9) (Table 5). The rate of perinatal death 246 
was 33.2% (3/10 – 95% CI 11.2-59.9) including two stillbirths and one neonatal death (four hours 247 
after birth of an extremely preterm infant). No case of fetal distress, Apgar score < 7 at five 248 
minutes, neonatal asphyxia, and admission to NICU was reported. Finally, none of the newborns 249 
showed signs of vertical transmission during the follow-up period (Table 7). 250 
 251 
SARS 252 
Six studies29-34 reported information on SARS infection during pregnancy. The rate of miscarriage 253 
for MERS infection was 39.1% (8/21 - 95% CI 20.2-59.8). The rate of PTB < 37 and 34 weeks of 254 
gestation was 15% (1/15 – 95% CI 0.3-45.6) and 28.9% (4/15 - 95% CI 10.7-51.6), respectively. 255 
pPROM and FGR occurred in 50% (1/2 – 95% CI 0.5-95.3) and 18.5% (2/15 – 95% CI 4.4-39.5) 256 
respectively, while no cases of preeclampsia were rported.  The rate of CD was 72.2% (7/9 – 95% 257 
CI 44.1-93.1) (Table 5). Fetal distress occurred in 35.9% (3/9 – 95% CI 12.0-64.4) of pregnancies, 258 
while no case of perinatal death, Apgar score < 7 at five minutes, and neonatal asphyxia was 259 
reported. There were no data on rates of admission to the NICU of infants born to infected mothers. 260 
Finally, none of the newborns showed signs of vertical transmission during the follow-up period 261 
(Table 7). 262 
 263 
It was not possible to perform a comprehensive pooled data synthesis on the incidence of pregnancy 264 
and perinatal outcomes according to the trimester of pregnancy at infection due to the very small 265 
number of included studies for each trimester of pregnancy. 266 
267 
COMMENT   268 
Main findings  269 
The findings from this systematic review show that more than 90% of hospitalized pregnant women 270 
affected by CoV infections present radiological sign  suggestive for pneumonia, detected either at 271 
chest x-ray or computerized tomography and the most c mmon symptoms are fever, cough and 272 
lymphopenia. Pregnancies affected by CoV infections have high rates of PTB before 37 and 34 273 
weeks, and miscarriage when the infection is acquired earlier in pregnancy. Preeclampsia and 274 
cesarean delivery are also more common than in the general population. The rate of perinatal 275 
mortality is about 10%, while the most common adverse perinatal outcome is fetal distress, with 276 
more than half of the newborns admitted in NICU. Importantly, clinical evidence of vertical 277 
transmission was found in none of the newborns included. 278 
 279 
Strengths and limitations 280 
To the best of our knowledge, this is the first systematic review exploring pregnancy and perinatal 281 
outcomes of CoV infections occurring during pregnancy. This comprehensive meta-analysis 282 
included all series published so far on this topic. 283 
The small number of cases in some of the included stu ies, their retrospective non-randomized 284 
design, and the lack of standardized criteria for the antenatal surveillance, management and timing 285 
of delivery of pregnancies affected by CoV infections represent the major limitations of this 286 
systematic review, thus making it difficult to draw any convincing evidence on this clinical 287 
management strategies. Furthermore, there is a possibility that some patients were included in more 288 
than one report, although two authors independently reviewed all the included studies, carefully 289 
focusing on the different Institutions reporting outcomes. Moreover, when focusing on the 290 
outcomes of COVID-19 infection, and particularly perinatal outcomes, reported data are intuitively 291 
limited to a very short-term follow-up period and thus infectious that occurred proximate to the 292 
delivery. This has the potential to overestimate thmagnitude of risks such as PTB and 293 
underestimate more longitudinal risks such as FGR. Additionally, it was not possible to extrapolate 294 
data about the rate of both spontaneous and iatrogenic PTB and indications for CD, that was 295 
performed in the majority of cases; furthermore, few outcomes, i.e. “fetal distress”, were not clearly 296 
defined, thus leading to some discrepancies in the results, like the rate of PTB < 34 weeks (15%) 297 
and the rate of newborns admitted to NICU (9%), particularly in COVID-19 infection. Another 298 
limitation of the present review was the lack of stratification of the analysis according to the 299 
gestational age at CoV infection due to the very small number of included studies for each trimester 300 
of pregnancy. We cannot assume that the rate of miscarr age and PTB should be attributed solely to 301 
the virus / infection, since there are no comparable control groups of uninfected women from the 302 
same time. It may be that the stress of the situation in the community contributed to some of these 303 
outcomes. Finally, we also included case reports and case series, thus facing a higher risk 304 
publication bias and decreasing the level of the evidence of our findings. 305 
 306 
Implications 307 
COVID-19 is the last CoV infection identified at the end of 2019 in Wuhan, a city in the Hubei 308 
Province of China.5 Currently, Europe has become the epicenter of the COVID-19 pandemic,6 but 309 
the infection has spread in more than 150 countries, l ading governments to adopt rigorous 310 
mitigation measures to reduce both the viral spread and its detrimental effects on healthcare systems 311 
and therefore on the whole economy of the countries.35 312 
Despite the relatively low mortality, one of the main concerns related to COVID-19 infection is the 313 
development of an acute respiratory distress syndrome, often requiring invasive ventilation, that is 314 
the clinical epiphenomenon of the viral pneumonia.6-7 315 
The lack of knowledge about COVID-19 infection has r ised urgent questions among physicians 316 
regarding clinical management and expected outcomes of the affected patients, and therefore, there 317 
is currently a compelling need of data to guide clini al decisions. 318 
Regarding pregnancy, the findings from this study found that radiological features suggestive for 319 
pneumonia can be found in almost all of the hospitalized pregnant women, usually presenting with 320 
fever, cough and lymphopenia similar to the non-pregnant population. Of note, serious conditions 321 
requiring admission to ICU and mechanical ventilation are significantly less common when 322 
compared with the two previous CoV infections (MERS and SARS). Similarly, we found no case of 323 
maternal death related to COVID-19 infection, while MERS and SARS infections caused a 324 
mortality rate in pregnant women ranging from 25% to 30%. 325 
In this systematic review, women affected by COVID-19 disease had higher rates of miscarriage, 326 
preterm birth, preeclampsia, while the babies had higher rates of perinatal mortality (7-11%) and of 327 
admission to NICU.  328 
Furthermore, as all the included studies reported data on hospitalized women, the reported rate of 329 
infection-related adverse outcomes, including either pr gnancy and perinatal outcomes, might not 330 
reflect the overall population of pregnant when who got infected with SARS-COV-2, and there may 331 
be a cohort of patients with no or mild symptoms whose pregnancy outcome is, as of yet, 332 
unknown.36 333 
More importantly, it should be emphasized that there a e no known neonatal symptoms and 334 
therefore no clinical evidence suggestive for vertical transmission, particularly when COVID-19 335 
infection occurs later in pregnancy. Unfortunately, the lack of data of first and early second 336 
trimester infection does not allow to determine whether in this case the infection may cause more 337 
severe perinatal outcomes and how to monitor the pregnancy once the infection has passed.1 338 
Based on the limited information from this study, COVID-19 cannot be considered as an indication 339 
for delivery and therefore the timing and mode of delivery should be individualized according to 340 
maternal clinical conditions or obstetric factors as usual (and not COVID-19 status alone), and the 341 
decision should involve a multidisciplinary team including maternal fetal doctors, neonatologists, 342 
anesthesiologists, and infective disease specialists. 343 
 344 
Conclusions 345 
In summary, with the limited data reported to date, mothers infected with coronavirus infections, 346 
including COVID-19, >90% of whom also had pneumonia, are at increased risks of miscarriage, 347 
preterm birth, preeclampsia, cesarean delivery, and their babies at higher risk of perinatal death and348 
admission to the NICU, compared to the general population. There have been no published cases of 349 
clinical evidence of vertical transmission. Evidenc is accumulating rapidly, so these data may need 350 
to be updated soon. 351 
 352 
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Table 1. General characteristics of the included studies. 451 
 452 
Author Year Study location Study 
period 




Mean maternal age 
Chen 2020 China 2020 Retrospective 9 Sars-CoV-2 29.9 
Wang 2020 China 2020 Case report 1 Sars-CoV-2 28 
Zhu 2020 China 2020 Retrospective 9 Sars-CoV-2 30.9 
Li 2020 China 2020 Case report 1 Sars-CoV-2 30 
Liu* 2020 Hubei, China 2020 Retrospective 11 Sars-CoV-2 32.5 
Liu 2020 Guangdong, China 2020 Retrospective 10 Sars-CoV-2 30.5 
Alfaraj 2019 Saudi Arabia 2015 Case series 2 Mers-CoV 34 
Jeong 2017 South Korea 2015 Case report 1 Mers-CoV 39 
Alserehi 2016 Saudi Arabia NR Case report 1 Mers-CoV 33 
Assiri 2016 Saudi Arabia 2012-2016 Case series 5 Mers-CoV 30.8 
Malik 2016 United Arab Emirates 2013 Case report 1 Mers-CoV 32 
Park 2016 South Korea 2015 Case report 1 Mers-CoV 39 
Payne 2015 Jordan 2012 Case report 1 Mers-CoV 39 
Yudin 2005 Canada NR Case report 1 Sars-CoV 33 
Wong 2004 Hong Kong, China 2003 Retrospective 12 Sars-CoV 30.6 
Lam 2004 China 2003 Retrospective 10 Sars-CoV 31.6 
Robertson 2004 USA 2003 Case report 1 Sars-CoV 36 
Schneider 2004 USA 2003 Case report 1 Sars-CoV NR 
Stockman 2004 USA 2003 Case report 1 Sars-CoV 38 
 453 
 454 
N, numbers; NR, not reported. 455 
 456 
*: preliminary data, pre-peer review version. 457 
  458 
Table 2. Pooled proportions of the different clinical symptoms and laboratory parameters in the overall population of pregnancies infected with CoV infection. 459 
 460 
Outcome Studies (n) Pregnancies (n/N) I2 (%) Pooled proportions (95% CI) 
Fever 17 64/76 8.2 82.57 (74.4-90.2) 
Cough 18 44/77 7.3 57.10 (45.8-68.0) 
Dyspnea 18 21/77 53.2 26.98 (18.2-36.8) 
Chest pain 17 3/66 0 8.61 (3.4-16.0) 
Pneumonia 16 54/57 0 91.84 (84.0-97.2) 
Lymphopenia 10 40/48 49.1 79.87 (60.4-93.9) 
Elevated liver enzymes 7 9/26 0 36.59 (20.4-54.5) 
Admission to ICU 18 22/70 58.1 34.10 (17.5-53.0) 
Need for mechanical ventilation 17 16/69 42.9 26.29 (13.3-41.9) 
Maternal death 19 9/79 0 12.30 (6.3-19.9) 
 461 
n/N, number of cases / total number of included pregnancies; CI, confidence interval; ICU, intensive care unit 462 
  463 
Table 3. Pooled proportions of treatment used in the overall population of pregnancies infected with Coronavirus infection. 464 
 465 
Outcome Studies (n) Pregnancies (n/N) I2 (%) Pooled proportions (95% CI) 
Antiviral therapy* 14 37/51 50 67.66 (47.2-85.1) 
Antibiotic therapy 14 49/52 27.9 89.26 (76.8-97.3) 
Steroids** 12 12/31 58.6 29.81 8.2-57.9) 
 466 
n/N, number of cases / total number of included pregnancies; CI, confidence interval. 467 
 468 
*Lopinavir/Ritonavir or Oseltamivir were the most common antiviral agents. Ribavirin was used in Wong et al. 469 
 470 
**Maternal (not fetal) indications  471 
  472 
Table 4. Pooled proportions of the different pregnancy outcmes in the overall population of pregnancies infected with Coronavirus infection. 473 
 474 
Outcome Studies (n) Pregnancies (n/N) I2 (%) Pooled proportions (95% CI) 
PTB <37 weeks 16 14/56 25.5 24.30 (12.5-38.6) 
PTB <34 weeks 16 11/56 1.9 21.79 (12.5-32.9) 
PE 6 2/19 0 16.21 (4.2-34.1) 
PPROM 8 6/34 0 20.72 (9.5-34.9) 
FGR 10 2/29 0 11.66 (3.2-24.4) 
Miscarriage 2 8/21 0 39.08 (20.2-59.8) 
Cesarean delivery 17 50/58 4 83.91 (73.8-91.9) 
 475 
n/N, number of cases / total number of included pregnancies; CI, confidence interval; PTB, preterm birth; PE, preeclampsia; pPROM, preterm prelabor ruptue of membranes; 476 
FGR, fetal growth restriction. 477 
 478 
  479 
Table 5. Pooled proportions of the different pregnancy outcmes explored in the present systematic review according to the type of viral infection. 480 
 481 
 Sars-CoV  Mers-CoV  Sars-CoV-2 


















PTB <37 weeks 5 1/15 15.03 
(0.3-45.6) 
31.8  6 0/11 0 
(0-28.9) 
0  6 14/32 41.11 
(25.6-57.6) 
0 
PTB <34 weeks 5 4/15 28.89 
(10.7-51.6) 
0  6 3/11 32.11 
(10.0-59.8) 
9.5  6 4/32 15.03 
(3.9-31.7) 
22.6 
Pre-eclampsia 2 0/2 0 
(0-67.0) 
0  2 1/7 19.10 
(1.1-51.3) 
0  3 1/12 13.55 
(1.2-36.0) 
0 
PPROM 2 1/2 50.0 
(0.5-95.3) 
46  2 0/2 0 
(0-54.4) 
0  5 5/31 18.78 
(0.8-33.5) 
0 
FGR 5 2/15 18.52 
(4.4-39.5) 
0  3 0/4 0 
(0-48.7) 
0  3 0/12 0 
(0-21.4) 
0 
Miscarriage 2 8/21 39.08  
(20.2-59.8) 
0  - - - -  - - - - 
Cesarean delivery 5 7/9 72.23 
(44.1-93.1) 
0  6 5/8 61.79 
(32.7-86.9) 





n/N, number of cases / total number of included pregnancies; CI, confidence interval; PTB, preterm birth; pPROM, preterm premature rupture of membranes; FGR, fetal 484 
growth restriction. 485 
 486 
 487 
  488 
Table 6. Pooled proportions of the different perinatal outcmes in the overall population of pregnancies infected with Coronavirus infection. 489 
 490 
Outcome Studies (n) Fetuses/Newborns (n/N) I2 (%) Pooled proportions (95% CI) 
Fetal distress 13 15/44 13.6 34.15 (20.3-49.5) 
Apgar score < 7 12 1/48 0 6.08 (1.3-13.9) 
Neonatal asphyxia 9 0/27 0 0 (0-15.7) 
Admission to NICU 4 3/12 76.3 57.16 (3.6-99.8) 
Perinatal death 16 5/60 0 11.11 (84.8-19.6) 
Vertical transmission 16 0/60 0 0 (0-10.7) 
 491 





  497 
Table 7. Pooled proportions of the different perinatal outcmes explored in the present systematic review according to the type of viral infection. 498 
43.  499 



















Fetal distress 5 3/9 35.89 
(12.0-64.4) 
0  4 0/5 0 
(0-44.5) 






4 0/4 0 
(0-60.2) 
0  3 0/3 0 
(0-56.9) 





4 0/4 0 
(0-60.2) 
0  2 0/2 0 
(0-67.0) 





- - - -  2 0/2 0 
(0-67.0) 






5 0/9 0 
(0-31.4) 
0  6 3/10 33.15 
(11.2-
59.9) 





6 0/14 0 
(0-24-0) 
0  4 0/4 0 
(0-60.2) 
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Figure legend 509 
Figure 1. Systematic review flowchart 510 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
 
PRISMA 2009 Flow Diagram 
 
Records identified through 
database searching 
























Additional records identified 
through other sources 
(n = 5) 
Records after duplicates removed 
(n = 538) 
Records screened 
(n = 538) 
Records excluded 
(n = 511) 
Full-text articles assessed 
for eligibility 
(n = 27) 
Full-text articles excluded, 
with reasons 
(n = 8) 
 
3: Chinese language 
3: Overlapping risk 
2: Review Studies included in 
qualitative synthesis 
(n = 19) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 19) 
Supplementary Table 1. Excluded studies and reason for the exclusion 
 
Author Year Title Reason for the exclusion 
Chen 2020 Pregnant Women With New Coronavirus Infection: A 
Clinical Characteristics and Placental Pathological Analysis 
of Three Cases 
Chinese language; 
A series of 11 cases from the same institution was published by Liu et al and was included in 
this systematic review 
Zhang 2020 Analysis of the pregnancy outcomes in pregnant women 
with COVID-19 in Hubei Province 
Chinese language 
Liu 2020 Coronavirus disease 2019 (COVID-19) during pregnancy: a 
case series 
Overlapping risk with Liu 2020  
(included with preliminary, pre-peer review data) 
Chen 2020 Infant born to mothers with a new Coronavirus (COVID-19) Same Institution of Zhu 2020 that was included in this systematic review 
Li 2005 Severe acute respiratory syndrome in neonats nd children Review about pediatric outcomes 
Ng 2004 SARS in newborns and children Review; 
Data on newborns born from infected mothers are report d in papers already included in this 
systematic review 
Shek 2003 Infant born to mothers with SARS It is likely that all – or the majority – of the cases presented in this series are also included in 
Wong 2004, that is already included in this systematic review 
Zhang 2003 Clinical analysis of pregnancy in second a  third trimesters 




































CoV, coronavirus; CT, computerized tomography; CXR, chest x-ray. 
  
Author Year Type of CoV Diagnosis of pneumonia 
Chen 2020 Sars-CoV-2 Typical sign of viral respirato y infection at CT 
Wang 2020 Sars-CoV-2 Bilateral ground glass opacities at CT 
Zhu 2020 Sars-CoV-2 Bilateral ground glass opacities, patchy consolidation, blurred borders at CT 
Li 2020 Sars-CoV-2 Patchy infiltrations at CXR 
Liu 2020 Sars-CoV-2 Ground glass opacities, crazy paving, consolidations at CT 
Jeong 2017 Mers-CoV Diffuse opacity in the lower lung area at CXR 
Alserehi 2016 Mers-CoV Bilateral infiltrates and lower lobe opacity at CXR 
Assiri 2016 Mers-CoV Bilateral infiltrates and lower lobe opacity at CXR 
Malik 2016 Mers-CoV Bilateral consolidations at CT 
Park 2016 Mers-CoV Patchy opacities in the lower lobes at CXR 
Yudin 2005 Sars-CoV Patchy lobe infiltrates at CXR 
Wong 2004 Sars-CoV Features suggestive for progressive air-space disease at CXR 
Lam 2004 Sars-CoV Features suggestive for atypical neumonia at CXR 
Robertson 2004 Sars-CoV Bilateral lower lobe infiltrates at CXR 
Schneider 2004 Sars-CoV Progressive pulmonary infiltrates at CXR 
Stockman 2004 Sars-CoV Diffuse infiltrates at CXR 
Supplementary Table 3. Pooled proportions of the different clinical symptoms and laboratory parameters according to the type of viral infection. 
 
 Sars-CoV  Mers-CoV  Sars-CoV-2 


















Fever 6 26/26 100 
(86.3-100) 
0  5 6/9 64.11 
(35.6-88.0) 
0  6 32/41 75.56 
(61.9-87.0) 
0 
Cough 6 20/26 74.21 
(57.1-88.2) 
0  6 7/10 65.59 
(38.8-88.0) 
0  6 17/41 42.02 
(28.0-56.7) 
0 
Dyspnea 6 11/26 48.79 
(27.5-70.3) 
17.5  6 7/10 66.85 
(40.1-88.8) 
0  6 3/41 8.89 
(2.4-19.0) 
0 
Chest pain 6 2/26 12.67 
(3.3-27.0) 
0  6 1/10 18.58 
(3.0-43.2) 
0  5 0/30 0 
(0-11.9) 
0 
Pneumonia 6 26/26 100 
(86.3-100) 
0  6 9/11 76.59 
(43.3-97.5) 
36.8  4 19/20 91.68 
(76.9-99.3) 
0 
Lymphopenia 4 24/24 100 
(87.1-100) 
0  2 1/2 50 
(0.5-95.3) 





3 5/14 37.91 
(14.7-64.5) 
4.3  1 1/1 100 
(25.0-100) 
-  3 3/11 29.55 
(8.6-56.6) 
0 
Admission to ICU 6 14/26 53.32 
(35.3-70.9) 
0  7 6/12 44.57 
(16.8-74.3) 
29  5 2/32 9.29 
(0.6-26.8) 
39.7 
Need for mechanical 
ventilation 
6 10/26 39.98 
(23.2-58.1) 
0  7 5/12 40.85 
(17.1-67.1) 





Maternal death 6 6/26 25.79 
(11.8-42.9) 
0  7 3/12 28.59 
(9.6-52.8) 





n/N, number of cases / total number of included pregnancies; CI, confidence interval; ICU, intensive care unit 
  
Supplementary Table 4. Pooled proportions of the need for therapy according to the type of viral infection. 
 
 Sars-CoV  Mers-CoV  Sars-CoV-2 


















Antiviral therapy* 5 13/16 66.87 
(30.0-94.5) 
41.9  4 2/4 50.0 
(6.8-93.2) 
0  5 22/31 74.83 
(41.0-97.0) 
70.9 
Antibiotic therapy 6 26/26 100 
(86.3-100) 
0  4 2/4 50.0 
(6.8-93.2) 
0  4 21/22 90.29 
(63.7-99.9) 
50.5 
Steroids** 5 11/16 50.08 
(14.8-85.3) 
45.4  4 0/4 0 
(0-60.2) 




n/N, number of cases / total number of included pregnancies; CI, confidence interval. 
 
*Lopinavir/Ritonavir or Oseltamivir were the most common antiviral agents. Ribavirin was used in Wong et al. 
 
**Maternal (not fetal) indications  
  
Supplementary Table 5. Quality assessment of the included studies 
 
Case series 
Author Year Selection Comparability Outcome  
Chen 2020     
Zhu 2020     
Liu 2020     
Liu 2020     
Alfaraj 2019     
Assiri 2016     
Wong 2003     
Lam 2003     
Case reports 
Author Year Selection Ascertainment Causality Reporting 
Wang 2020     
Li 2020     
Jeong 2017     
Alserehi 2016     
Malik 2016     
Park 2016     
Payne 2015     
Yudin 2005     
Robertson 2004     
Schneider 2004     




































NR, not reported. 
Author Year Type of CoV Details on perinatal deaths 
Zhu 2020 Sars-CoV-2 1 Neonatal death:  The baby was delivered at a gestational age of 34+5 weeks and admitted 30 minutes after 
delivery due to shortness of breath and moaning. Eiht days later, he developed refractory shock, multiple 
organ failure, and disseminated intravascular coagulation, which were treated by the transfusion of platelets, 
suspended red blood cells, and plasma; he died on the 9th day. 
Liu 2020 Sars-CoV-2 1 stillbirth, no other available details 
Assiri 2016 Mers-CoV 1 stillbirth:  At 34 weeks, the mother complained shortness of breath since 3 days and was admitted for 
elevated blood pressure and 3+ proteinuria consistent with preeclampsia, and pneumonia was diagnosed by 
means of chest radiography. Fetal heart tones were abs nt, and intrauterine fetal demise was suspected. A 
stillborn infant was delivered the same day. 
1 neonatal death:  At 24 weeks gestation, the mother presented to the hospital on 23 October with cough and 
myalgia, and chest radiography at admission showed a right lower lobe opacity. Her respiratory status 
deteriorated during hospitalization, and she was admitted to the ICU on 28 October for ARDS requiring 
intubation and mechanical ventilation. On 31 October, the patient delivered a 240-gram infant by cesaran 
delivery. The infant died 4 hours after birth. 
Payne 2015 Mers-CoV 1 stillbirth:  During the outbreak period, the mother’s acute respi atory symptoms (fever, rhinorrhea, fatigue, 
headache, and cough) occurred concurrently with vaginal bleeding and abdominal pain on the seventh day of 
illness, and she spontaneously delivered a stillborn infant. 
